Eur J Heart Fail 22:196213 Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, McMurray JJV, Kosiborod MN, Butler J (2020) Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization
Nobody disputes thats too high
In diabetes management, the need for continued GLP-1 therapy relates to the progressive nature of beta-cell dysfunction
How to obtain the P value from a confidence interval
One of the most important signals in this network is GLP-1, short for glucagon-like peptide-1
For enhanced effectiveness, GLP-1 therapy is integrated with personalized lifestyle modifications